Valeant Pharmaceuticals (VRX) New CEO, Joe Papa, Could Be Headed For A Massive Payoff

Mark Melin

Published onApril 28, 2016

Updated on May 13, 2021

Valeant Pharmaceuticals appears to be drawing on its Michael Pearson play book in setting up a structure to lure former Perrigo CEO Joe Papa to head the troubled drug company roll-up business model.

Valeant Pharmaceuticals Perrigo Valeant Pharmaceuticals — Valeant Pharmaceuticals

What executive would want to take over Valeant Pharmaceuticals? A well-compensated one

On the surface, the Valeant CEO job may seem a daunting challenge.

The company is facing Congressional and U.S. Securities and Exchange Commission investigations, has a $30 billion debt load that is dragging on earnings and, a clear focus of investigation is the company's restating of earnings from 2014 and 2015 in a tangled web of...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mark Melin

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.

Valeant Pharmaceuticals (VRX) New CEO, Joe Papa, Could Be Headed For A Massive Payoff

What executive would want to take over Valeant Pharmaceuticals? A well-compensated one

Login required to continue reading.

Get Your Business News